ArticleDiscover oncology2025
Deep learning model outperforms traditional models in clinical data-based prognostic prediction for adult-type diffuse glioma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThis study aims to systematically compare traditional statistical methods and machine learning approaches for survival prediction in adult-type diffuse glioma (ADG), evaluating their performance, interpretability, and clinical applicability.
methodsUsing two public datasets and one private retrospective cohort, four models (Cox Proportional Hazards, Random Survival Forest, Neural Multi Task Logistic Regression, and DeepSurv) were developed and validated. Missing values were handled in three different ways and subjected to sensitivity analysis.
resultsIn both the internal test cohorts and two external validation cohorts, the neural network-based deep learning model outperformed the random survival forest and Cox proportional hazards model, with the DeepSurv model demonstrating the most robust performance. Key prognostic factors included age, molecular pathology, chemotherapy, extent of resection, extent of disease, and radiotherapy. Sensitivity analysis confirmed model stability. The model has been packaged and made publicly available.
conclusionFor retrospective real-world ADG patient data with high heterogeneity and partial missingness, the DeepSurv model demonstrates superior survival prediction performance and stability compared to conventional approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.